Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes

Study acronym: MARITIME-T2D-3
StatusNot Yet Recruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Amgen
169 trials monitored
See 11 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Trial Details
NCT Number NCT07866066
Lead Sponsor Amgen
Conditions
(from sponsor)		 Diabetes Mellitus, Type 2
Related terms Body Weight, Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 1,300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov